Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparative efficacy of rivaroxaban and warfarin to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation in a real world setting.

Trial Profile

Comparative efficacy of rivaroxaban and warfarin to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation in a real world setting.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Aug 2014

At a glance

  • Drugs Rivaroxaban (Primary) ; Warfarin
  • Indications Atrial fibrillation; Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Janssen
  • Most Recent Events

    • 09 Aug 2014 New trial record
    • 04 Jun 2014 Results presented at the 19th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top